SE0101999L - Method for detecting lymphomas and lymphoproliferative diseases - Google Patents

Method for detecting lymphomas and lymphoproliferative diseases

Info

Publication number
SE0101999L
SE0101999L SE0101999A SE0101999A SE0101999L SE 0101999 L SE0101999 L SE 0101999L SE 0101999 A SE0101999 A SE 0101999A SE 0101999 A SE0101999 A SE 0101999A SE 0101999 L SE0101999 L SE 0101999L
Authority
SE
Sweden
Prior art keywords
sample
pcr
determining
efficiency
genes
Prior art date
Application number
SE0101999A
Other languages
Swedish (sv)
Other versions
SE521026C2 (en
SE0101999D0 (en
Inventor
Pierre Aaman
Anders Staalberg
Mikael Kubista
Original Assignee
Canag Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canag Diagnostics Ab filed Critical Canag Diagnostics Ab
Priority to SE0101999A priority Critical patent/SE521026C2/en
Publication of SE0101999D0 publication Critical patent/SE0101999D0/en
Priority to BR0210094-0A priority patent/BR0210094A/en
Priority to EP02736406A priority patent/EP1399592A1/en
Priority to CA002445099A priority patent/CA2445099A1/en
Priority to MXPA03010959A priority patent/MXPA03010959A/en
Priority to JP2003502244A priority patent/JP2004532641A/en
Priority to RU2004100112/13A priority patent/RU2004100112A/en
Priority to PCT/SE2002/001093 priority patent/WO2002099135A1/en
Priority to AU2002309423A priority patent/AU2002309423B2/en
Publication of SE0101999L publication Critical patent/SE0101999L/en
Publication of SE521026C2 publication Critical patent/SE521026C2/en
Priority to US10/694,979 priority patent/US20040132069A1/en
Priority to US11/617,214 priority patent/US20070184470A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Determining efficiency of a polymerase chain reaction (PCR), where the number of copies of a nucleic acid sequence in a test sample is determined, comprises amplification of DNA by PCR, registering the number of amplification cycles required to obtain a certain amount of product (CT), and estimating the efficiency of the PCR in the sample from the dependence of CT on the dilution factor. Determining efficiency of a polymerase chain reaction (PCR), where the number of copies of a particular nucleic acid sequence in a test sample is determined, comprises amplification of DNA by PCR of the sample itself, or a diluted stock solution of the sample itself, and one or more controlled dilutions of the sample, and registering the number of amplification cycles required to obtain a certain amount of product (CT), and estimating the efficiency of the PCR in the sample from the dependence of CT on the dilution factor. Independent claims are included for the following: (1) diagnosing and/or classifying a disease by comparing the expression ratio of two genes by determining the ratio of the corresponding mRNAs in a sample; (2) monitoring a diseases progress, where the expressions of two or more genes are compared; (3) making a disease prognosis, where the expressions of two or more genes are compared; (4) comparing the presence of splicing variants of a gene by determining their relative amounts; (5) comparing the activities of alternative promoters by determining the relative amounts of their transcripts; (6) determining the amount of a virus or bacteria in a sample; and (7) diagnostic testing for cancer, including lymphoma, where at lest the kappa:lambda expression is determined
SE0101999A 2001-06-06 2001-06-06 Determining efficiency of a polymerase chain reaction (PCR), useful for clinical diagnosis, comprises estimating the efficiency of PCR in the sample from the dependence of the threshold cycle on the dilution factor for each of the genes SE521026C2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE0101999A SE521026C2 (en) 2001-06-06 2001-06-06 Determining efficiency of a polymerase chain reaction (PCR), useful for clinical diagnosis, comprises estimating the efficiency of PCR in the sample from the dependence of the threshold cycle on the dilution factor for each of the genes
AU2002309423A AU2002309423B2 (en) 2001-06-06 2002-06-05 Method to measure gene expression ratio of key genes
MXPA03010959A MXPA03010959A (en) 2001-06-06 2002-06-05 Method to measure gene expression ratio of key genes.
EP02736406A EP1399592A1 (en) 2001-06-06 2002-06-05 Method to measure gene expression ratio of key genes
CA002445099A CA2445099A1 (en) 2001-06-06 2002-06-05 Method to measure gene expression ratio of key genes
BR0210094-0A BR0210094A (en) 2001-06-06 2002-06-05 Method for measuring the expression ratio of a gene in the standard gene class
JP2003502244A JP2004532641A (en) 2001-06-06 2002-06-05 Method of measuring gene expression ratio of key gene
RU2004100112/13A RU2004100112A (en) 2001-06-06 2002-06-05 METHOD FOR MEASURING THE RELATIONSHIP OF GENE EXPRESSION OF KEY GENES
PCT/SE2002/001093 WO2002099135A1 (en) 2001-06-06 2002-06-05 Method to measure gene expression ratio of key genes
US10/694,979 US20040132069A1 (en) 2001-06-06 2003-10-28 Method to measure gene expression ratio of key genes
US11/617,214 US20070184470A1 (en) 2001-06-06 2006-12-28 Method to measure gene expression ratio of key genes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101999A SE521026C2 (en) 2001-06-06 2001-06-06 Determining efficiency of a polymerase chain reaction (PCR), useful for clinical diagnosis, comprises estimating the efficiency of PCR in the sample from the dependence of the threshold cycle on the dilution factor for each of the genes

Publications (3)

Publication Number Publication Date
SE0101999D0 SE0101999D0 (en) 2001-06-06
SE0101999L true SE0101999L (en) 2002-12-07
SE521026C2 SE521026C2 (en) 2003-09-23

Family

ID=20284377

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101999A SE521026C2 (en) 2001-06-06 2001-06-06 Determining efficiency of a polymerase chain reaction (PCR), useful for clinical diagnosis, comprises estimating the efficiency of PCR in the sample from the dependence of the threshold cycle on the dilution factor for each of the genes

Country Status (1)

Country Link
SE (1) SE521026C2 (en)

Also Published As

Publication number Publication date
SE521026C2 (en) 2003-09-23
SE0101999D0 (en) 2001-06-06

Similar Documents

Publication Publication Date Title
US20220002788A1 (en) Competitive probes for engineering signal generation
WO2017223026A1 (en) Detection of rna using ligation actuated loop mediated amplification methods and digital microfluidics
CN102329876A (en) Method for measuring nucleotide sequence of disease associated nucleic acid molecules in sample to be detected
Rubio-Guerri et al. Simultaneous diagnosis of Cetacean morbillivirus infection in dolphins stranded in the Spanish Mediterranean sea in 2011 using a novel Universal Probe Library (UPL) RT-PCR assay
CN113999901B (en) Myocardial specific methylation markers
KR20120030047A (en) Methods for nucleic acid quantification
KR101829668B1 (en) Nucleic acid chip and Reference Substance for Obtaining Bind information of sigle-stranded nucleic acid and Biomolecule, Manufacturing Method Thereof, and Method and apparatus for analyzing Biomolecules Using Nucleic acid chip and Reference Substances
WO2023021978A1 (en) Method for examining autoimmune disease
SE0101999L (en) Method for detecting lymphomas and lymphoproliferative diseases
WO2021039777A1 (en) Method for examining rheumatoid arthritis
CN114959001A (en) Product for diagnosing acute myocardial infarction and application thereof
WO2021060311A1 (en) Method for detecting brain tumor
Tao et al. Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays
JP6226460B2 (en) Nucleic acid quantification method, primer set used therein, DNA chip and assay kit, and method for determining resident bacteria using the same
Dahlhausen Future veterinary diagnostics
JP7242081B2 (en) Methods for detecting small RNA
KR101998204B1 (en) Digital PCR primer set for diagnosis of prostate cancer and uses thereof
CN106636464A (en) Characteristic miRNAs in Ebola virus infected blood and application of characteristic miRNAs
Liu et al. High-fidelity CRISPR/Cas13a trans cleavage-driven assembly of single quantum dot nanosensor for ultrasensitive detection of long noncoding RNAs in clinical breast tissues
JP2022025456A (en) Method for inspecting multiple sclerosis
KR20210142359A (en) Rt-pcr composition for detecting feline coronavirus
CN112301096A (en) Novel nucleic acid probe labeling method
CN113345580A (en) Alzheimer disease detection reagent, diagnosis device and application
JP2013031378A (en) Method of evaluating effect of chemical substance on living body
CN117535448A (en) Whole genome capture kit suitable for type 1 and type 2 blue-ear viruses and application

Legal Events

Date Code Title Description
NUG Patent has lapsed